DONG-A ST
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, including Stillen for the treatment of gastritis; Zydena for erectile dysfunction treatment; Motilitone for use in functional dyspepsia treatment; Sivextro an oxazolidinone class antibiotic; and Suganon for diabetes treatment.
DONG-A ST
Industry:
Biotechnology Health Care Manufacturing
Founded:
1932-01-01
Status:
Active
Contact:
82 2 920 8114
Similar Organizations
China Pharma
Develops, manufactures and markets generic and brand pharmaceutical products for western & traditional Chinese medicines.
DS Pharma Animal Health
DS Pharma Animal Health is an R&D company manufactures and markets pharmaceutical products for animal.
Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medical packing materials.
Pharmacia
Pharmacia Corporation develops, manufactures, and markets prescription pharmaceutical products and services.
WUHAN KEQIAN BIOLOGY CO LTD
Wuhan Keqian Biology Co., Ltd. develops, manufactures, and sells veterinary biological products including pig and poultry vaccinations.
Current Employees Featured
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-11-02 | Antiva Biosciences | Dong-A ST investment in Series D - Antiva Biosciences | 31 M USD |
More informations about "Dong-A ST"
DONG-A ST
Organization; Donga-A ST CP Milestones; Compliance Ethical Value; ISO37001 (ABMS) Business Areas. Dong-A ST Product. Ethical Products; Product News; Medical Device โฆSee details»
๋์์์์คํ๋ฉ์ค - DONG-A
Specialized in manufacturing prescribed drugs and medical devices and the related international businesses, Dong-A ST sees its future in biological anti-tumor agents and immune disease โฆSee details»
Dong-A ST, STGen Bio, ST Pharm's Triangular Partnership at
CEO Park reiterates Dong-A ST's shift from 'chemical to bio' in 2024, confident in the company's ability to establish a unique position in the global bio market. ... "The organization, divided into โฆSee details»
๋์ST - donga-st.com
Dong-A ST is currently exporting novel drugs, generics, and biologics produced in cGMP facilities to 32 countries worldwide through its globally competitive overseas business network. We โฆSee details»
๋์์์์คํ๋ฉ์ค - DONG-A
Dong-A Otsuka became an official beverage supplier for Korea Baseball Organization. Mar ST Pharm entered into an agreement with Ewha University-Industry Collaboration Foundation for jointly develop gene therapy delivery โฆSee details»
Dong-A ST Co., Ltd. - Drug pipelines, Patents, Clinical trials - Patsnap
Explore Dong-A ST Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 149 clinical trials, 84 news, and 62 literature, Disease Domain:Neoplasms, Infectious Diseases, โฆSee details»
DONG-A ST
DA-3880 is a biosimilar of darbepoetin alfa (Aranesp®, Nesp®). Dong-A ST performed phase 1 clinical trial in EU and confirmed PK bioequivalence and similarity of PD, safety and โฆSee details»
Dong-A ST - Crunchbase Investor Profile & Investments
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, including Stillen for the treatment of gastritis; โฆSee details»
OUR STORY - ๋์ST
Dong-A ST has consistently pursued domestic and international licensing/partnerships to enhance the strength of our R&D. To become a global leader, we will actively pursue M&A and open โฆSee details»
Dong-A ST: Department Head of Oncology & Inflammation โฆ
Please send your message or CV to [email protected] if you are interested this role by 10/31/2024. Key responsibility : โข Lead teams engaged in basic research/preclinical & โฆSee details»
KASBP - Dong-A ST: Multiple position in the R&D center, โฆ
For comprehensive details regarding each positionโs responsibilities and requirements, kindly refer to the following sections. If you are interested this role, please send your message or CV โฆSee details»
Dong-A ST Secures European Approval for Stelara Biosimilar โฆ
5 days ago SEOUL, South Korea โ Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, IMULDOSA (Project Name: DMB-3115, Active โฆSee details»
Dong-A ST. Information about the issuer. . News and credit ratings ...
Dong-A ST is a Korean-based pharmaceutical company. The company was founded in 1932 and is located in Seoul, South Korea. General information. ... Operating organization Address. 64, โฆSee details»
Dong-A ST Co. Ltd Company Profile & Data: stocks, market cap
Jul 1, 2024 Detailed Description. Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, โฆSee details»
DA-5207 - Drug Targets, Indications, Patents - Synapse - Patsnap
DA-5207, Initially developed by Dong-A ST Co., Ltd., Now, its global highest R&D status is Phase 1, Active Org.: Dong-A ST Co., Ltd.. ... Active Organization. Dong-A ST Co., Ltd. Inactive โฆSee details»
Dong-A ST sichert Zulassung für das Stelara-Biosimilar IMULDOSA โฆ
5 days ago Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) gibt bekannt, dass sein Stelara-Biosimilar IMULDOSA (Projektname: DMB-3115, aktiver Wirkstoff: Ustekinumab) am 18. โฆSee details»
DongA ST-
Dong-A ST Co. Ltd., acting as Controller 64, Cheonho-Daero, Dongdaemun-Gu Seoul 02587, Republic of Korea email: [email protected] telephone: +82 2 920 8254 Data Protection โฆSee details»
DONG-A ST
2019 12 Dong-A ST reduces the size of 'Stillen Tablet' for gastritis. 10 Dong-A ST cooperates with Ildong Pharmaceutical for the joint promotion of โDong-A Gaster Tab.โ 09 Dong-A ST launches โฆSee details»
DONG-A ST
On October 1, Dong-A ST (Chairman Eom Dae-sig) announced that the company will cooperate with Ildong Pharmaceutical ... You have the right to request for the receipt or the transfer to โฆSee details»